IN2014KN00996A - - Google Patents

Info

Publication number
IN2014KN00996A
IN2014KN00996A IN996KON2014A IN2014KN00996A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A IN 996KON2014 A IN996KON2014 A IN 996KON2014A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A
Authority
IN
India
Prior art keywords
dexmedetomidine
administering
methods
subject matter
disclosed subject
Prior art date
Application number
Other languages
English (en)
Inventor
De Rocha Marcelo Garcia
Wayne Wisemandle
Dennis J Stalker
Edward Koo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN00996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014KN00996A publication Critical patent/IN2014KN00996A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN996KON2014 2011-10-14 2012-09-27 IN2014KN00996A (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547626P 2011-10-14 2011-10-14
US13/343,693 US20130096170A1 (en) 2011-10-14 2012-01-04 Methods of treating pediatric patients using dexmedetomidine
US13/471,403 US8324260B1 (en) 2011-10-14 2012-05-14 Methods of treating pediatric patients using dexmedetomidine
PCT/US2012/057652 WO2013055528A1 (en) 2011-10-14 2012-09-27 Methods of treating pediatric patients using dexmedetomidine

Publications (1)

Publication Number Publication Date
IN2014KN00996A true IN2014KN00996A (enExample) 2015-09-04

Family

ID=47226666

Family Applications (1)

Application Number Title Priority Date Filing Date
IN996KON2014 IN2014KN00996A (enExample) 2011-10-14 2012-09-27

Country Status (23)

Country Link
US (8) US20130096170A1 (enExample)
EP (2) EP2766014B1 (enExample)
JP (5) JP6270727B2 (enExample)
KR (3) KR20200019791A (enExample)
CN (2) CN109700806A (enExample)
AU (3) AU2012321246C1 (enExample)
BR (1) BR112014008983A2 (enExample)
CA (2) CA2851780C (enExample)
CY (1) CY1121041T1 (enExample)
DK (1) DK2766014T3 (enExample)
ES (1) ES2685814T3 (enExample)
HK (1) HK1200333A1 (enExample)
HR (1) HRP20181378T1 (enExample)
HU (1) HUE039671T2 (enExample)
IL (2) IL232070A0 (enExample)
IN (1) IN2014KN00996A (enExample)
LT (1) LT2766014T (enExample)
MX (1) MX362626B (enExample)
PL (1) PL2766014T3 (enExample)
PT (1) PT2766014T (enExample)
RS (1) RS57660B1 (enExample)
SI (1) SI2766014T1 (enExample)
WO (1) WO2013055528A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
KR20180095732A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
EP3054932B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
TWI629061B (zh) * 2013-10-07 2018-07-11 美商帝國製藥美國股份有限公司 包含右美托嘧啶(dexmedetomidine)經皮組成物之疼痛處理用方法及組成物
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
US11017330B2 (en) * 2014-05-20 2021-05-25 Elasticsearch B.V. Method and system for analysing data
WO2016025989A1 (en) 2014-08-18 2016-02-25 Epat Pty Ltd A pain assessment method and system
CN104784174A (zh) * 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
BR112019006955A2 (pt) * 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN106539778A (zh) * 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
US11783046B2 (en) 2017-04-26 2023-10-10 Elasticsearch B.V. Anomaly and causation detection in computing environments
US11621969B2 (en) 2017-04-26 2023-04-04 Elasticsearch B.V. Clustering and outlier detection in anomaly and causation detection for computing environments
CN108042533B (zh) * 2017-12-25 2020-11-13 苏州格兰科医药科技有限公司 右美托米定在制备用于预防和/或抑制创伤性脑损伤后的神经元死亡的药物组合物中的用途
EP3813828A4 (en) * 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
CA3111793A1 (en) * 2018-09-12 2020-03-19 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
US20220051802A1 (en) * 2018-12-13 2022-02-17 Dignity Health System and method for detection and monitoring of over sedation to prevent harm to patients
US10817669B2 (en) 2019-01-14 2020-10-27 International Business Machines Corporation Automatic classification of adverse event text fragments
CN109793709A (zh) * 2019-02-22 2019-05-24 青岛农业大学 一种斑海豹用复方注射剂及其制备方法
US11000488B2 (en) * 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CA3145388A1 (en) * 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US20230165520A1 (en) * 2020-04-17 2023-06-01 Bioventures, Llc Methods and systems for predicting the effect of inhaled and infused anesthetics
KR102815903B1 (ko) 2021-12-21 2025-05-30 충남대학교산학협력단 감염 환자에서 반코마이신 최적 용량을 결정하는 방법
EP4386768A1 (en) * 2022-12-13 2024-06-19 Koninklijke Philips N.V. Active sleep apnea case finding and scheduling system and method of operation thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025176701A1 (en) * 2024-02-19 2025-08-28 Rigshospitalet Novel pediatric composition of nasal dexmedetomidine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
JPS6058890A (ja) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd 感熱記録紙用填剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
PT679088E (pt) 1992-09-29 2002-12-31 Inhale Therapeutic Syst Administracao pulmonar de fragmentos activos de hormona paratiroide
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
DK0774963T3 (da) 1994-08-08 2001-01-29 Debiopharm Sa Farmaceutisk stabilt oxaliplatin-præparat
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6716867B1 (en) * 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
US20080308444A1 (en) 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8100890B2 (en) * 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
US7896843B2 (en) * 2008-10-15 2011-03-01 Bioquiddity, Inc. Special purpose fluid dispenser
JP5536661B2 (ja) 2008-10-30 2014-07-02 国立大学法人 岡山大学 局所麻酔用組成物
KR101859486B1 (ko) 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
US20110152271A1 (en) 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (fr) 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
AU2019203564A1 (en) 2019-06-13
HRP20181378T1 (hr) 2018-10-19
CA2851780A1 (en) 2013-04-18
JP6270727B2 (ja) 2018-01-31
AU2012321246C1 (en) 2017-11-02
JP2022008828A (ja) 2022-01-14
HK1200333A1 (en) 2015-08-07
WO2013055528A1 (en) 2013-04-18
CA2978258A1 (en) 2013-04-18
CA2851780C (en) 2017-11-28
JP2014528474A (ja) 2014-10-27
EP2766014B1 (en) 2018-07-18
US8507542B2 (en) 2013-08-13
US20190269657A1 (en) 2019-09-05
KR20190029775A (ko) 2019-03-20
US20130096170A1 (en) 2013-04-18
DK2766014T3 (en) 2018-09-24
EP2766014A4 (en) 2015-06-24
SI2766014T1 (sl) 2018-11-30
HUE039671T2 (hu) 2019-01-28
MX362626B (es) 2019-01-28
US9314449B2 (en) 2016-04-19
ES2685814T3 (es) 2018-10-11
AU2012321246B2 (en) 2017-05-04
JP2020073529A (ja) 2020-05-14
US20140005243A1 (en) 2014-01-02
JP6640164B2 (ja) 2020-02-05
LT2766014T (lt) 2018-08-27
EP3446691A1 (en) 2019-02-27
AU2017206211B2 (en) 2019-02-28
JP2023179764A (ja) 2023-12-19
EP2766014A1 (en) 2014-08-20
KR20200019791A (ko) 2020-02-24
PT2766014T (pt) 2018-10-11
US20160067220A1 (en) 2016-03-10
CN103957906A (zh) 2014-07-30
US8324260B1 (en) 2012-12-04
US20130096172A1 (en) 2013-04-18
BR112014008983A2 (pt) 2017-05-02
US20130096171A1 (en) 2013-04-18
AU2012321246A1 (en) 2014-05-01
IL249991A0 (en) 2017-03-30
US20210137891A1 (en) 2021-05-13
MX2014004548A (es) 2015-02-12
JP2018027971A (ja) 2018-02-22
CN109700806A (zh) 2019-05-03
AU2017206211A1 (en) 2017-08-03
RS57660B1 (sr) 2018-11-30
IL232070A0 (en) 2014-05-28
KR20140094539A (ko) 2014-07-30
CY1121041T1 (el) 2019-12-11
PL2766014T3 (pl) 2019-02-28

Similar Documents

Publication Publication Date Title
IN2014KN00996A (enExample)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2012023623A3 (ja) ハンター症候群の治療剤
NZ732507A (en) Improved compositions for treating muscular dystrophy
GB2491328A (en) Immediate/delayed drug delivery
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
GB2491327A (en) Delayed prolonged drug delivery
HK1218560A1 (zh) 组成与方法
EP2406765A4 (en) DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
EP2702994A3 (en) Methods of administering pirfenidone therapy
PH12014500386A1 (en) Combination treatment for hepatitis c
GB201111485D0 (en) Drug composition and its use in therapy
NZ714963A (en) Compositions and methods for treating anemia
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
IN2014CN00315A (enExample)
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
GB201022049D0 (en) Methods
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
RU2011108787A (ru) Способ лечения больных красным плоским лишаем слизистой полости рта